Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Invite your friends, family, colleagues or clients to an exceptional black-tie event in the heart of London. Every ticket, every bid, every moment helps us move closer to a cure.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Join the type 1 diabetes community and come together, raising awareness and vital funds for T1D.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & events > News > Vertex trial of Zimislecel cellular therapy enables ten of 12 participants to remain insulin independent
The FORWARD-101 trial for the therapy, known as VX-880 or zimislecel, takes lab grown beta cells and infuses them into the liver of the participants. These cells are then able to mimic the destroyed cells in the pancreas which produce insulin (pancreatic islets), removing the need for insulin injections. Zimislecel requires long-term medication to stop the immune system from rejecting the cells.
In this study, 12 out of 12 patients were free of severe low blood sugar (hypoglycaemia) and spent 70% of the time within their glucose target range. Ten out of 12 participants had insulin independence and were not injecting any insulin after 365 days.
One of two doses of the cellular therapy were given in this trial (either one half dose or one full dose) and their success was measured using a biomarker called C-peptide. The presence of C-peptide levels in the blood directly relate to insulin activity. All 12 participants in the full-dose cohort had detectable C-peptide levels before and after meals, showing that the implanted cells were successfully producing insulin.
Cellular therapies are the closest thing currently being researched which could be referred to as a cure. This clinical trial is an exciting step towards people with type 1 diabetes (T1D) producing their own insulin independently.
These new results are promising for cell-therapies in T1D. Further investigations are required with larger, more diverse populations to increase the evidence that lab grown beta cells can be given to patients to successfully treat T1D and help millions of people.
At Breakthrough T1D UK, we played a key role in the early stages of this progress. In 2000, we funded Professor Doug Melton’s work to create insulin-producing beta cells from stem cells, which he successfully achieved in 2014. He went on to form Semma Therapeutics to develop these cells into potential cures for type 1 diabetes. Our T1D Fund later invested in Semma, which was acquired by Vertex. In 2021, their therapy VX-880 received fast-track designation from the FDA.
Rachel Connor, Director of Research Partnerships, says: ‘Today’s news brings a new wave of hope to those with T1D, as the journey toward cures for T1D reaches another new milestone. The results presented at the ADA conference are so exciting because they tell the story of people with T1D regaining the ability to live without the need for insulin therapy. This represents a landmark moment in T1D research. At Breakthrough T1D, we are proud to support the foundational research that made this innovation possible, and we remain committed to our ultimate goal – a world without T1D’
Find out about the global research we're funding to find cures and better treatments for T1D.
Get information and advice about living well with type 1.
Join our mission to find cures for T1D and, until then, make life better for people living with it.
If you use the Dexcom G6 app on your Android smartphone, the newest Android 16 operating system may disrupt how the app functions.
We're calling for urgent reform as new report reveals older people with T1D are systematically failed by health and social care services.
Breakthrough T1D has helped organise an event hosted by Tomislav Sokol titled ‘Accelerating Breakthroughs to Address Unmet Needs in Type 1 Diabetes.’
People living with type 1 diabetes (T1D) across the UK now have more choice in how to manage their condition, with the mylife CamAPS FX app now available on iPhones.
Immunotherapy, beta cell replacement, smart insulins – we’re driving research in the most promising areas to find cures and better treatments for type 1 diabetes.
